EGFR and non-small cell lung carcinoma: Following the introduction of these EGFR TKIs, life expectancy in NSCLC patients with EGFR mutations increased from 21.6 to 28.2 months in OS [4,5,6] and from 9.5 to 13.1 months in progression-free survival (PFS) [4,7,8].